Overview

Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Aldesleukin
Interleukin-2